

Scientific Program

Day 1

August 10, 2015

08:30-09:30 Registrations

Gates Suite



09:30-09:55

Opening Ceremony

Keynote Forum

09:55-10:00 **Introduction**

10:00-10:30

Greg Koski

Alliance for Clinical Research Excellence and Safety, USA

10:30-11:00

Angela van der Salm

DADA Consultancy B.V. Netherlands

Networking and Refreshment Break: 11:00-11:15

11:15-11:45

Peter Lannon

Lanpharm Consulting T/A Lanpharm Services, UK

11:45-12:15

Kieran O'Donnell

TMC Pharma Services, UK

12:15-12:45

Alistair Coates

Oviya MedSafe, UK

Track 1: Concept of Pharmacovigilance and its Significance and Scope

Track 7: Pharmacovigilance and Risk Management

Track 8: Clinical Research and Statistics

Session Chair: Kieran O'Donnell, TMC Pharma Services, UK

Session Co-Chair: Peter Lannon, Lanpharm Consulting T/A Lanpharm Services, UK

Session Introduction

12:45-13:10

MedDRA SMQs: Physician ratings of important terms for diagnosis of cardiac failure and acute pancreatitis- A Delphi study

Michelle perry, Aspen Pharmacare Trading Limited, Ireland

Lunch Break 13:10-14:10

Workshop

14:10-15:10

Inefficiencies in pharmacovigilance: What we can do now and what could be done in the future

Giovanni Furlan, Helsinn Birex, Ireland

15:10-15:35

Over a century of Alzheimer and still no cause in sight: Is pharmacovigilance asleep on the job?

G Robert Jones, Cancer Research Unit, UK

Networking & Refreshment Break 15:35-15:50

Workshop

15:50-16:25

The EU-RMP - Planning risk management in a feasible fashion

Angela van der Salm, DADA Consultancy B.V, Netherlands

16:25-16:45

Extended EudraVigilance medicinal products dictionary (xevmpd)

Alistair Coates, Oviya MedSafe, UK

Workshop

16:45-17:15

Tomorrow, today: Systems approaches to enhance pharmacovigilance and risk management

Greg Koski, Alliance for Clinical Research Excellence and Safety, USA

- 17:15-17:35 **V is for Venn diagrams**
 Kriss Harris, Eisai, UK
- 17:35-18:00 **Creating high quality statistical graphs for publications**
 Kriss Harris, Eisai, UK

Day 2 August 11, 2015

Gates Suite

Track 2: Pre-Clinical and Clinical Trials & Case Report
Track 3: Clinical Trials on Drugs used in Various Disorders, Pharmacotherapy and Pharmacotherapeutics
Track 4: Adverse Drug Reactions
Track 10: Good Pharmacovigilance Practice and Pharmacoepidemiology

Session Chair: Subodh Bhardwaj, Arable Corporation, USA
Session Co-Chair: Pramod Wable, Daiichi Sankyo Development Ltd., UK

- 10:00-10:25 **Combining quantitative and qualitative methods in signal detection and evaluation in pharmacovigilance**
 Michelle Perry, Aspen Pharmacare Trading Limited, Ireland

Workshop

- 10:25-11:25 **Title Vaccine vigilance- Towards strengthening pharmacovigilance**
 Subodh Bhardwaj, Arable Corporation, USA

Networking & Refreshment Break 11:25-11:40

- 11:40-12:05 **Evaluation of the clinical indications, adverse drug reactions, and Finasteride use in patients with benign prostatic hyperplasia in Poland**
 Tomasz Zabkowski, Military Medical Institute, Poland

- 12:05-12:30 **ADR is a threat more to children and women than adult male**
 Sagar D Kadam, Babanrao Pachpute Vichardhara Trust's Group of Institutions, India

- 12:30-12:55 **The regulation of allogeneic human cells and tissue products as biomaterials**
 Kazuo Yano, Tokyo Women's Medical University, Japan

Lunch Break 12:55-14:00

- 14:00-14:25 **Pharmacovigilance: State of pharmacovigilance in developing countries: Lomie's hospital (East Region / Cameroon) in regard to the harmonization of new European regulations of pharmacovigilance**
 Carolle Laure Matene Kpoumie, ONMC, Paris

Workshop

- 14:25-15:25 **Lean, six sigma and ISO and their applications in clinical trials/research**
 Pramod Wable, Daiichi Sankyo Development Ltd, UK

- 15:25-15:50 **Challenges and issues in pharmacovigilance of herbal medicines in India**
 Mahek Arora, Amity University, India

Panel Discussions

Networking & Refreshment Break 15:50-16:05

16:05-17:05 Poster Presentations

- PC 01 **The influence of co-prescribed GABA-ergic drugs on anti-depressant compliance in patients with depression: A prospective study in a South African private healthcare cohort**
 Martha Susanna Lubbe, North-West University (NWU), South Africa
- PC 02 **The importance of pharmacovigilance, now and in the future**
 Michelle perry, Aspen Pharmacare Trading Limited, Ireland
- PC 03 **Effect of Stachys mialhesi de noe on the inflammation induced by hyperhomocysteinemia in cardiovascular diseases**
 Sakina Zerizer, University of Constantine, Algeria
- PC 04 **Uncommon serum creatine phosphokinase and lactic dehydrogenase increase during diosmin therapy: Two case reports**
 Giulia Milano, University of Genova, Italy
- PC 05 **An observational study of cutaneous adverse drug reactions in a teaching hospital**
 Deepti Chopra, Hamdard Institute of Medical Sciences and Research, India
- PC 06 **Attitude and awareness of adverse drug reaction reporting by health professionals in seven hospitals in the holy city of makkah, kingdom of Saudi Arabia**
 Naif Al Hazmi, Bradford University, KSA

- PC 07 **Pharmacokinetic-model based microfluidic multi-organ-on-a-chip for testing whole-body response to xenobiotic compounds**
Jong Hwan, Hongik University, South Korea
- PC 08 **Sakina Zerizer, University of Constantine, Algeria**
Martha Susanna Lubbe, North-West University (NWU), South Africa

Day 3 August 12, 2015

Gates Suite

Track 5: Pharmacokinetics and Pharmacodynamics

Track 6: Pharmacy Practices and its Challenges

Track 12: Clinical Pharmacology and Biopharmaceutics

Session Chair: Subodh Bhardwaj, Arable Corporation, USA

Session Co-Chair: Doaa A Ghareeb, Alexandria University, Egypt

10:00-10:25 Medication administration errors in pediatric ward: An observational study

Zayed Alsulami, Alkharj Military Industries Corporation Hospital, KSA

Workshop

10:25-11:25 Potential molecular mechanism of *Berberise Vulgaris* extract, berberine and berberine chitosan nanoparticles in Alzheimer treatment

Doaa A Ghareeb, Alexandria University, Egypt

Networking & Refreshment Break 11:25-11:40

11:40-12:05 Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA treat): Study protocol for an on-going randomized controlled trial

Pascal Klaus, Charite - Universitätsmedizin Berlin, Germany

12:05-12:30 Rapid, accurate and simple microfluidic device based on fluorescent read-out immunoassay for the determination of oral anticoagulants compounds in treated patients

J Pablo Salvador, CIBER-BBN, Spain

Lunch Break 12:30-13:30

Award Ceremony

Bookmark your dates

4th Annual

European Pharma Congress

June 13-15, 2016 Berlin, Germany

Website: europe.pharmaceuticalconferences.com

e-mail: pharmaeurope@conferenceseries.com; pharmaeurope@conferenceseries.net

3rd World Congress on

Pharmacology

August 01-03, 2016 Birmingham UK

Website: pharmacology.pharmaceuticalconferences.com

e-mail: pharmacology@conferenceseries.com; pharmacology@conferenceseries.net

5th International Conference and Exhibition on

Pharmacovigilance & Clinical Trials

September 19-21, 2016 Vienna, Austria

Website: pharmacovigilance.pharmaceuticalconferences.com

e-mail: pharmacovigilance@pharmaceuticalconferences.com; pharmacovigilance@conferenceseries.net

OMICS Group Inc.

2360 Corporate Circle, Suite 400
 Henderson, NV 89074-7722, USA
 Ph: +1-888-843-8169
 Fax: +1-650-618-1417
contact@omicsgroup.com

OMICS International

5716 Corsa Ave., Suite 110, Westlake
 Los Angeles, CA 91362-7354, USA
 Ph: +1-650-268-9744
 Fax: +1-650-618-1414
contact.americas@omicsonline.org

OMICS Group

SEZ Unit, Building No. 20, 9th Floor
 APIIC Layout, HITEC City
 Hyderabad-500081, Telangana, INDIA
 Ph: 040-40131823, 040-47482222
contact.asiapacific@omicsonline.org

Toll free

USA & Canada: +1-800-216-6499
 Australia: +1-800-651-097
 Europe: 0805-080048